EUCTR2016-001607-23-HU进行中（未招募）1 期
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Children 6 to <12 Years of Age with Uncontrolled Persistent Asthma - Liberty Asthma Voyage
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 785
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Children 6 to <12 years of age, with a physician diagnosis of persistent asthma for =12 months prior to Screening, based on clinical history and examination, pulmonary function parameters according to Global initiative for asthma (GINA) 2015 Guidelines and the following criteria:
- •-Existing background therapy of medium-dose inhaled corticosteroids (ICS) with second controller medication (ie, long-acting ß2 agonist [LABA], leukotriene receptor antagonist [LTRA], long acting muscarinic antagonist [LAMA], or methylxanthines) or high-dose ICS alone or high dose ICS with second controller, for at least 3 months with a stable dose =1 month prior to Screening Visit 1.
- •-Pre-bronchodilator forced expiratory volume in 1 second (FEV1) =95% of predicted normal or pre bronchodilator FEV1/forced vital capacity (FVC) ratio <0.85 at Screening and Baseline Visits.
- •-Reversibility of at least 10% in FEV1 after the administration of 200 to 400mcg (2 to 4 puff inhalations with metered-dose inhaler [MDI] of albuterol/salbutamol or 45 to 90 mcg (2 to 4 puffs with MDI) of levalbuterol/levosalbutamol reliever medication before randomization (up to 3 opportunities during the same visit are allowed with a maximum of 12 puffs of reliever medication if tolerated by the patient).
- •-Must have experienced within 1 year prior to Screening Visit 1, any of the following events:
- •-Treatment with a systemic corticosteroid (SCS, oral or parenteral), as prescibed by a healthcare professional for worsening asthma at least once or,
- •-Hospitalization or emergency room visit for worsening asthma
- •- Evidence of uncontrolled asthma, with at least one of the following criteria during the 4 (±1) weeks Screening Period:
- •-Asthma Control Questionnaire–Interviewer Administered (ACQ-IA) ACQ-5 score =1.5 on at least one day of the Screening Period.
- •-Use of reliever medication (ie, albuterol/salbutamol or levalbuterol/levosalbutamol), other than as a preventive for exercise induced bronchospasm, on 3 or more days per week, in at least one week during the Screening Period.
- •-Sleep awakening due to asthma symptoms requiring use of reliever medication at least once during the Screening Period.
- •-Asthma symptoms 3 or more days per week in at least one week during the Screening Period.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 785
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Patients <6 or =12 years of age.
- •-Patients with <16 kg bodyweight.
- •-Any other chronic lung disease (cystic fibrosis, bronchopulmonary dysplasia, etc) which may impair lung function.
- •-A subject with any history of life threatening asthma (ie, extreme exacerbation that requires intubation).
- •-Co-morbid disease that might interfere with the evaluation of investigational medicinal product (IMP).
研究者
相似试验
已完成
3 期
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabetes post Worsening Heart FailureNL-OMON50219exicon Pharmaceuticals, Inc.65
进行中（未招募）
1 期
Effect of Efpeglenatide on Cardiovascular OutcomesType 2 diabetes mellitusMedDRA version: 21.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-002954-35-FIsanofi-aventis recherche & développement5,000
进行中（未招募）
1 期
Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular RiskType 2 diabetes mellitusChronic kidney diseaseMedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2017-002644-32-NOSANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT16,154
进行中（未招募）
1 期
GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Crohn’s DiseaseModerately to Severely Active Crohn's DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2020-006165-11-DEJanssen-Cilag International NV350
撤回
2 期
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple-dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults with Compensated Cirrhosis from Nonalcoholic Steatohepatitis (NASH)NL-OMON53971Bristol-Myers Squibb6